Gamcemetinib - Bristol-Myers Squibb
Alternative Names: BMS-986371; CC-99677Latest Information Update: 07 Apr 2025
At a glance
- Originator Celgene Corporation
- Class Anti-inflammatories
- Mechanism of Action MAP-kinase-activated kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Ankylosing spondylitis; Inflammation
Most Recent Events
- 14 Nov 2024 Efficacy and adverse events data from a phase II trial in Ankylosing Spondylitis presented at the ACR Convergence 2024 (ACR-2024)
- 27 Mar 2024 Pharmacokinetics and adverse events data from a phase I trial (In volunteers) presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics 2024 (ASCPT-2024)
- 26 Oct 2023 Discontinued - Phase-I for Inflammation (In volunteers) in USA, United Kingdom (PO) prior to October 2023 (Bristol-Myers Squibb pipeline, October 2023)